Share: HIGHLIGHTS Further validation for Aroa's Myriad™ from two clinical studies and peer-reviewed publications in Journal of Wound Care. One study shows high success rates, from use of Myriad™ in tissue reconstruction after surgical treatment of Hidradenitis Suppurativa, an inflammatory skin condition affecting around 1% of the adult population. A second study showed 100% success rates from use of Myriad™ when patients underwent surgical reconstruction of exposed vital structures such as bone and tendon, demonstrating the utility of Myriad™ for both implant procedures and dermal reconstruction and across a wide range of surgical procedures. The national regulatory authority of India, the Central Drugs Standard Control Organisation (CDSCO), has approved Myriad™, Endoform® Natural and Endoform® Antimicrobial. India has significant market potential with a large volume of acute and chronic wounds and distribution expected to commence in second half of the 2021 calendar year.